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“Even	  the	  stones	  that	  have	  been	  	  
placed	  in	  one's	  path	  can	  be	  	  
made	  into	  something	  beautiful”	  	  Johann	  Wolfgang	  von	  Goethe	  
	   	  
Preface	  	  This	  dissertation	  was	  completed	  as	  a	  cotutelle	  collaboration	  (joint	  supervision	  agreement)	  between	   the	   Justus	   Liebig	   University	   (JLU)	   of	   Giessen	   and	   the	   University	   of	   Padova	  (UNIPD).	  The	  thesis	  is	  based	  on	  experimental	  work	  carried	  out	  in	  Germany	  at	  the	  Institute	  of	  Organic	  Chemistry	  and	  Institute	  of	  Biochemistry	  of	  the	  JLU	  Giessen	  (from	  January	  2010	  till	  September	  2013,	  under	  the	  supervision	  of	  Prof.	  Dr.	  R.	  Göttlich)	  as	  well	  as	  in	  Italy	  at	  the	  Department	  of	  Pharmaceutical	  and	  Pharmacological	  Sciences	  of	  the	  UNIPD	  (from	  October	  2013	  till	  March	  2015,	  under	  the	  supervision	  of	  Prof.	  Dr.	  B.	  Gatto).	  	  The	   present	   work	   is	   prepared	   as	   a	   cumulative	   doctoral	   thesis,	   consisting	   of	   several	  scientific	  articles	  already	  published	  or	  submitted	  for	  publication,	  which	  are	   incorporated	  into	   the	   thesis	   as	   successive	   chapters	   (Chapters	   2‒4).	   A	   general	   introduction	   to	   the	  theoretical	   background	   and	   an	   overall	   summary	   of	   the	   main	   findings	   are	   presented	   in	  Chapter	   1.	   Moreover,	   this	   chapter	   describes	   the	   research	   aim	   and	   the	   relationships	  between	  the	  individual	  publications.	  	  	  At	   this	   point,	   I	   would	   like	   to	   express	   my	   gratitude	   to	   the	   German	   National	   Academic	  Foundation	  (Studienstiftung	  des	  deutschen	  Volkes)	  for	  providing	  me	  a	  PhD	  scholarship.	  I	  am	   also	   very	   grateful	   to	   the	   International	   Giessen	  Graduate	   Centre	   for	   the	   Life	   Sciences	  (GGL)	  and	  the	  German	  Academic	  Exchange	  Service	  (DAAD)	  for	  awarding	  me	  a	  travel	  grant.	  The	   financial,	   educational	   and	   ideational	   support	   enabled	  me	   to	   successfully	   accomplish	  this	  binational,	  interdisciplinary	  dissertation.	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Abstract	  	  DNA	  alkylating	  agents	  represent	  a	  major	  class	  of	  first-­‐line	  chemotherapeutic	  drugs	  in	  the	  fight	   against	   cancer.	   Among	   them,	   nitrogen	  mustards	   are	   the	   oldest	   and	   clinically	  most	  effective	   anticancer	   agents	   in	   use	   today.	   They	   exert	   their	   primary	   cytotoxic	   actions	   by	  covalently	  binding	  to	  DNA	  bases	  and	  thereby	  causing	  DNA	  strand	  cleavage,	  which	  can	  lead	  to	   the	   inhibition	  of	   cell	   division	   and	  ultimately	   cell	   death.	  However,	   adverse	   side	   effects	  and	   the	   emergence	   of	   nitrogen	   mustard	   drug	   resistance	   are	   apparent	   drawbacks	   that	  restrict	  their	  therapeutic	  utility.	  One	  approach	  to	  overcome	  these	  limitations	  is	  the	  design	  and	  subsequent	   structural	  optimisation	  of	  novel	   alkylating	  agents	  based	  on	   the	  mustard	  pharmacophore.	  	  The	   objectives	   of	   the	   work	   described	   in	   this	   doctoral	   thesis	   are	   (a)	   the	   synthesis	   of	  nitrogen-­‐linked	  bis-­‐3-­‐chloropiperidines	  as	  simplified	  analogues	  of	  the	  antibiotic	  593A	  and	  (b)	  the	  biological	  evaluation	  of	   their	  DNA	  alkylating	  properties.	  These	   investigations	  aim	  at	   the	   elucidation	   of	   the	  molecular	  mechanism	   of	   action	   of	   this	   new	   class	   of	   piperidine	  mustards.	  The	  compounds	  examined	  in	  this	  research	  project	  are	  designed	  to	  explore	  the	  effect	   of	   different	   linker	   structures	   on	   alkylation	   activity,	   allowing	   the	   determination	   of	  structure‒activity	  relationships.	  	  Based	  on	  preliminary	  studies	  in	  our	  group,	  a	  series	  of	  bis-­‐3-­‐chloropiperidines	  with	  flexible	  alkyl	   groups,	   a	   conformationally	   restrained	   cyclohexyl	   moiety,	   rigid	   aromatic	   or	   lysine	  ester	   linkers	  was	  successfully	  prepared.	  The	  bidirectional	  synthetic	  strategy	   involves	  the	  reductive	   amination	   of	   the	   respective	   diamine	   linker	   with	   2,2-­‐dimethylpent-­‐4-­‐enal	   and	  subsequent	  chlorination,	   followed	  by	   iodide-­‐catalysed	  cyclisation	  of	   the	  unsaturated	  bis-­‐
N-­‐chloroamine	   to	   yield	   the	   target	   compound.	   Thus,	   a	   small	   library	   of	   bis-­‐3-­‐chloropiperidine	   derivatives	   has	   been	   assembled	   to	   provide	   an	   experimental	   proof-­‐of-­‐concept	  study.	  	  The	   ability	   of	   the	   synthesised	   compounds	   to	   alkylate	   double-­‐stranded	   DNA	   (plasmids	  pAT153	   and	   pBR322;	   22-­‐mer	   oligonucleotide)	   was	   ascertained	   by	   comparative	   DNA	  cleavage	   assays	   using	   gel	   electrophoresis	   methods.	   The	   results	   demonstrate	   that	   the	  investigated	  bis-­‐3-­‐chloropiperidines	  exhibit	  significant	  DNA	  alkylation	  activities,	  superior	  to	   the	   nitrogen	   mustard	   antitumour	   drug	   chlorambucil.	   Our	   studies	   reveal	   that	   DNA	  cleavage	  occurs	  primarily	  through	  reactions	  with	  guanines	  via	  a	  DNA	  nicking	  mechanism.	  Experimental	   evidence	   indicates	   the	   presence	   of	   agent-­‐induced	   DNA	   adducts.	  Furthermore,	  the	  reactive	  aziridinium	  ion	  formation	  is	  verified	  by	  ESI	  mass	  spectrometry.	  	  The	   findings	   from	   this	   survey	   substantiate	   that	   the	   linker	   structure	   has	   a	   considerable	  impact	   on	   DNA	   alkylation	   efficiency	   of	   bis-­‐3-­‐chloropiperidines.	   On	   the	   basis	   of	   the	  obtained	  results,	  it	  is	  concluded	  that	  the	  flexibility	  and	  composition	  of	  the	  linker	  region	  are	  crucial	  features.	  In	  particular,	  the	  introduction	  of	  rigid	  aromatic	  motifs	  or	  an	  ester	  function	  leads	   to	   a	   reduced	   DNA	   cleavage	   activity,	   whereas	   DNA-­‐affinic	   chromophores	   likely	  contribute	   to	   favourable	   DNA	   interactions.	   These	   established	   structure‒activity	  relationships	   might	   offer	   the	   possibility	   for	   the	   modulation	   of	   reactivity	   of	   bis-­‐3-­‐chloropiperidines	  for	  the	  development	  of	  effective	  new	  DNA	  alkylating	  agents.	  	  

Kurzfassung	  	  DNA-­‐alkylierende	   Agenzien	   repräsentieren	   eine	   bedeutsame	   Gruppe	   von	   First-­‐line	  Chemotherapeutika	   im	   Kampf	   gegen	   Krebs.	   Unter	   ihnen	   gehören	   die	   Stickstoff-­‐Lost-­‐Verbindungen	   zu	  den	  ältesten	  und	  wirkungsvollsten	  Zytostatika,	  welche	   in	  der	  heutigen	  Krebstherapie	   Verwendung	   finden.	   Die	   primäre	   zytotoxische	   Wirkung	   dieser	  Substanzklasse	  beruht	  auf	  kovalente	  Bindungen	  an	  DNA	  und	  daraus	  resultierenden	  DNA-­‐Strangbrüchen,	  was	  zu	  einer	  Hemmung	  der	  DNA-­‐Replikation	  und	  letztendlich	  zum	  Zelltod	  führen	   kann.	   Allerdings	   liegen	   ihre	   wesentlichen	   Nachteile	   in	   zahlreich	   auftretenden	  Nebenwirkungen	   und	   verstärkter	   Resistenzentwicklung,	   wodurch	   ihr	   therapeutischer	  Nutzen	   eingeschränkt	   wird.	   Ein	   vielsprechender	   Ansatz	   diese	   Defizite	   zu	   überwinden,	  besteht	   im	  Design	   sowie	   der	   anschließenden	   strukturellen	  Optimierung	   von	   neuartigen,	  auf	  dem	  Stickstoff-­‐Lost-­‐Pharmakophor	  basierenden	  Alkylanzien.	  	  Die	   vorliegende	  Dissertation	   befasst	   sich	  mit	   den	   folgenden	   Zielsetzungen:	   (a)	   Synthese	  von	  Stickstoff-­‐verbrückten	  Bis-­‐3-­‐chlorpiperidinen	  als	  strukturell	  vereinfachte	  Analoga	  des	  Antibiotikums	   593A;	   (b)	   Biologische	   Evaluation	   der	   dargestellten	   Derivate	   hinsichtlich	  ihrer	   DNA-­‐alkylierenden	   Eigenschaften.	   Das	   grundlegende	   Ziel	   der	   Forschungsarbeit	   ist	  die	   Aufklärung	   des	   molekularen	   Mechanismus	   dieser	   neuen	   Klasse	   von	   Piperidin-­‐Lost-­‐Verbindungen.	  Die	  im	  Rahmen	  des	  Vorhabens	  geplanten	  Zielstrukturen	  sind	  dahingehend	  gewählt,	   den	  Einfluss	   verschiedener	   Linker	   auf	   die	  Alkylierungsaktivität	   zu	  untersuchen	  und	  Struktur-­‐Aktivitäts-­‐Beziehungen	  abzuleiten.	  	  Aufbauend	  auf	  eigenen	  sowie	  in	  unserer	  Arbeitsgruppe	  erfolgten	  Vorarbeiten,	  wurde	  eine	  Reihe	  von	  Bis-­‐3-­‐chlorpiperidinen	  mit	  flexiblen	  Kohlenwasserstoff-­‐,	  einem	  konformationell	  eingeschränkten	   Cyclohexan-­‐,	   starren	   aromatischen	   oder	   Lysinester-­‐Linkern	   erfolgreich	  hergestellt.	   Die	   etablierte	   bidirektionale	   Synthesestrategie	   beinhaltet,	   neben	   der	  reduktiven	   Aminierung	   von	   2,2-­‐Dimethyl-­‐4-­‐pentenal	   mit	   dem	   jeweiligen	   Diamin-­‐Linker	  und	  anschließender	  Chlorierung,	   als	   zentralen	   Schritt	   die	   Iodid-­‐katalysierte	  Cyclisierung	  ungesättigter	  Bis-­‐N-­‐chloramine	  zu	  den	  gewünschten	  Zielverbindungen.	  Demgemäß	  wurde	  im	  Verlauf	   der	  Arbeit	   eine	   kleine	   Substanzbibliothek	   von	  Bis-­‐3-­‐chlorpiperidin-­‐Derivaten	  aufgebaut,	   mit	   dem	   Ziel	   eine	   experimentelle	   Grundsatzstudie	   (Proof	   of	   Concept)	  durchzuführen.	  	  Die	  Fähigkeit	  der	  synthetisierten	  Testsubstanzen	  doppelsträngige	  DNA	  (Plasmide	  pAT153	  und	   pBR322;	   22-­‐mer	   Oligonukleotid)	   zu	   alkylieren,	   wurde	   in	   vergleichenden	   DNA-­‐Spaltungsexperimenten	   mittels	   gelelektrophoretischer	   Methoden	   untersucht.	   Die	  Ergebnisse	  zeigen,	  dass	  die	  evaluierten	  Bis-­‐3-­‐chlorpiperidine	  signifikante,	  im	  Vergleich	  zu	  dem	   Antitumormittel	   Chlorambucil	   (Stickstoff-­‐Lost-­‐Derivat)	   deutlich	   überlegene,	   DNA-­‐Alkylierungsaktivitäten	   aufweisen.	   Unsere	   Studien	   demonstrieren,	   dass	   die	   beobachtete	  DNA-­‐Spaltung	   hauptsächlich	   durch	   Reaktionen	   mit	   Guanin	   nach	   einem	   DNA-­‐Nicking-­‐Mechanismus	   (Induktion	   von	   Einzelstrangbrüchen)	   erfolgt.	   Experimentelle	   Befunden	  belegen	   darüber	   hinaus	   die	   Generierung	   von	   DNA-­‐Addukten.	   Weiterhin	   konnte	   die	  Bildung	   des	   reaktiven	   intermediären	   Aziridinium-­‐Ions	   durch	   ESI-­‐Massenspektrometrie	  eindeutig	  nachgewiesen	  werden.	  	  	  
Die	  durch	  diese	  Arbeit	  gewonnen	  Erkenntnisse	  bestätigen,	  dass	  die	  Linker-­‐Struktur	  einen	  entscheidenden	   Einfluss	   auf	   die	   DNA-­‐Alkylierungseffizienz	   von	   Bis-­‐3-­‐chlorpiperidinen	  ausübt.	   Zusammenfassend	   lässt	   sich	   anhand	   der	   Forschungsergebnisse	   schlussfolgern,	  dass	   die	   Flexibilität	   sowie	   die	   strukturelle	   Beschaffenheit	   des	   Linkers	   maßgebliche	  Faktoren	   darstellen.	   Insbesondere	   wird	   durch	   die	   Einführung	   von	   aromatischen	  Strukturmotiven	   oder	   einer	   Ester-­‐Funktionalität	   die	   DNA-­‐Spaltungsaktivität	   herabsetzt,	  wogegen	  DNA-­‐affine	  Chromophore	  voraussichtlich	  zu	  günstigen	  DNA-­‐Wechselwirkungen	  beitragen.	   Anhand	   der	   aufgestellten	   Struktur-­‐Aktivitäts-­‐Beziehungen	   besteht	   die	  Möglichkeit	  durch	  strukturelle	  Modifizierungen	  die	  Reaktivität	  von	  Bis-­‐3-­‐chlorpiperidinen	  gezielt	  zu	  steuern	  und	  infolgedessen	  neuartige,	  effektive	  DNA-­‐Alkylanzien	  zu	  entwickeln.	  	  	  	  	  	  
Riassunto	  	  Agenti	  alchilanti	  del	  DNA	  rappresentano	  una	  classe	  importante	  di	  chemioterapici	  di	  prima	  linea	  nella	   battaglia	   contro	   il	   cancro.	   Tra	   questi	   agenti	   antitumorali	   le	   mostarde	   azotate	   sono	   il	  gruppo	   clinicamente	   efficace	   e	   più	   antico	   attualmente	   in	   uso.	   Essi	   esercitano	   la	   loro	   azione	  citotossica	   primaria	   attraverso	   legami	   covalenti	   tra	   i	   nucleotidi,	   causando	   scissione	  del	  DNA.	  Questi	  danni	  al	  DNA	  possono	  portare	  all'inibizione	  della	  divisione	  cellulare	  ed	  infine	  alla	  morte	  cellulare.	  Gli	  effetti	  collaterali	  e	  l'emergere	  di	  resistenza	  alle	  mostarde	  azotate,	  tuttavia,	  sono	  gli	  svantaggi	  principali	  che	  limitano	  la	  loro	  utilità	  terapeutica.	  Un	  approccio	  che	  cerca	  di	  superare	  queste	   limitazioni	   è	   il	   design	   e	   la	   successiva	   ottimizzazione	   strutturale	   dei	   nuovi	   agenti	  alchilanti	  basati	  sul	  farmacoforo	  delle	  mostarde	  azotate.	  	  Gli	  obiettivi	  del	  lavoro	  di	  ricerca	  descritti	  in	  questa	  tesi	  di	  dottorato	  sono	  (a)	  la	  sintesi	  di	  bis-­‐3-­‐cloropiperidine	   legate	   all’azoto	   mediante	   diversi	   linker	   come	   analoghi	   semplificati	  dell'antibiotico	   593A	   e	   (b)	   la	   valutazione	   biologica	   delle	   loro	   proprietà	   alchilanti	   del	   DNA.	  Questi	   studi	   hanno	   lo	   scopo	   di	   chiarire	   il	   meccanismo	  molecolare	   d'azione	   di	   questa	   nuova	  classe	   di	   mostarde	   piperidiniche.	   I	   composti	   esaminati	   in	   questo	   lavoro	   sono	   progettati	   per	  esplorare	   l'effetto	   delle	   diverse	   strutture	   del	   linker	   sull'attività	   alchilante,	   permettendo	   la	  determinazione	  delle	  relazioni	  struttura-­‐attività.	  Sulla	  base	  degli	  studi	  preliminari	  nel	  nostro	  gruppo,	  è	  stata	  preparata	  con	  successo	  una	  serie	  di	  bis-­‐3-­‐cloropiperidine	  unite	  da	   gruppi	   alchilici	   flessibili,	   da	   altri	   conformazionalmente	   limitati	  come	  un	  gruppo	  cicloesilico,	  gruppi	   rigidi	  aromatici	  e	  altri	  uniti	  da	  una	   lisina	  esterificata	  con	  vari	   sostituenti.	   La	   sintesi	   bidirezionale	   prevede	   l'amminazione	   riduttiva	   del	   rispettivo	  diammina-­‐linker	   con	   2,2-­‐dimetil-­‐4-­‐pentenale	   e	   successiva	   clorurazione,	   seguita	   da	   ioduro	  catalizzata	   ciclizzazione	   della	   bis-­‐N-­‐cloroamina	   insaturo	   a	   fornire	   il	   composto	   desiderato.	   In	  questo	   modo	   una	   piccola	   libreria	   di	   derivati	   bis-­‐3-­‐cloropiperidine	   è	   stata	   costituita	   per	  effettuare	  uno	  studio	  proof-­‐of-­‐concept.	  La	  capacità	  dei	  composti	  sintetizzati	  di	  alchilare	  il	  DNA	  a	  doppio	  filamento	  (plasmidi	  pAT153	  e	  pBR322,	  oligonucleotide	  22-­‐mer)	  è	  stata	  investigata	  da	  esperimenti	  di	  scissione	  del	  DNA	  (DNA	  cleavage	   assay)	   utilizzando	  metodi	   di	   elettroforesi	   su	   gel.	   I	   risultati	   dimostrano	   che	   le	   bis-­‐3-­‐cloropiperidine	   indagate	   presentano	   significative	   attività	   di	   alchilazione	   del	   DNA,	   superiori	   al	  chemioterapico	  clorambucile,	  un	  derivato	  della	  mostarda	  azotata.	  Infatti,	  i	  nostri	  studi	  rivelano	  che	   la	   scissione	   del	   DNA	   avviene	   principalmente	   attraverso	   reazioni	   con	   la	   base	   guanina,	  mediante	   un	   meccanismo	   di	   “nicking”	   (l'incisione	   di	   un	   filamento	   del	   DNA).	   Le	   evidenze	  sperimentali	  indicano	  che	  gli	  agenti	  sono	  capaci	  di	  indurre	  addotti	  di	  DNA.	  Inoltre,	  la	  formazione	  dello	  ione	  aziridinio	  reattivo	  è	  stata	  verificata	  con	  analisi	  di	  spettrometria	  di	  massa	  (ESI-­‐MS).	  	  I	  risultati	  di	  questo	  lavoro	  comprovano	  che	  la	  struttura	  del	  linker	  ha	  un	  considerevole	  impatto	  sull'efficienza	   alchilante	   delle	   bis-­‐3-­‐cloropiperidine.	   Sulla	   base	   dei	   dati	   ottenuti,	   si	   può	  concludere	   che	   la	   flessibilità	   e	   la	   composizione	   del	   linker	   sono	   fattori	   determinanti.	   In	  particolare,	   l'introduzione	  di	  gruppi	  aromatici	  rigidi	  oppure	  una	  funzione	  esterea	  porta	  ad	  una	  ridotta	   attività	   di	   clivaggio	   del	   DNA,	   mentre	   cromofori	   affini	   al	   DNA	   probabilmente	  contribuiscono	   alle	   interazioni	   favorevoli.	   Le	   relazioni	   tra	   struttura	   ed	   attività	   osservate	   per	   i	  derivati	  testati	  potrebbero	  offrire	  la	  possibilità	  di	  modulare	  la	  reattività	  di	  bis-­‐3-­‐cloropiperidine	  e	  quindi	  costituiscono	  una	  base	  per	  lo	  sviluppo	  di	  nuovi	  agenti	  alchilanti	  efficaci.	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CHAPTER	  1:	  	  
	  
Introduction	  and	  Synopsis	  	  
1.1	  Chemical	  Warfare	  against	  Cancer	  	  More	   than	   40	   years	   have	   passed	   since	  U.S.	   President	   Richard	  Nixon	   declared	   a	   “war	   on	  cancer”	   (National	   Cancer	   Act	   of	   1971)[1]	   and	   “despite	   dramatic	   scientific	   gains,	   cancer	  remains	  an	  undaunted	  killer.”[2]	  Today,	  one	  in	  every	  eight	  death	  is	  due	  to	  cancer	  and	  there	  are	  about	  14	  million	  new	  cancer	   cases	  globally	  each	  year.[3]	   In	  2012	  approximately	  32.6	  million	   people	   had	   been	   diagnosed	   with	   cancer.	   Within	   the	   next	   two	   decades,	   cancer-­‐related	  deaths	  are	  predicted	  to	  rise	  from	  an	  estimated	  8.2	  million	  annually	  to	  13	  million	  a	  year.[4]	  These	  alarming	  statistics	  underscore	  the	  imperative	  need	  for	  continued	  research	  in	  preventing,	  detecting	  and	  treating	  cancer.	  	  	  	  
	  
Figure	  1:	  Schematic	  representation	  of	  the	  DNA	  damage	  pathway	  which	  can	  trigger	  a	  variety	  of	  cellular	  responses	  culminating	   in	   the	  development	  of	  cancer.	  Modified	   from	  Sigma-­‐Aldrich®:	  DNA	  Damage	  and	  Repair,	  BioFiles	  2007,	  2.4,	  20.[7]	  	  	  Cancer	  is	  a	  general	  term	  for	  diseases	  characterised	  by	  uncontrolled	  multiplication	  of	  cells.	  These	   abnormal	   cells	   are	   able	   to	   invade	   surrounding	   tissue	   or	   spread	   throughout	   the	  body.	  This	  spreading	  process	  is	  called	  metastasis.	  All	  cancer	  types	  are	  caused	  by	  mutations	  in	  DNA	  which	  occur	  when	  there	  are	  alterations	  in	  the	  sequence	  of	  DNA	  bases.[5]	  DNA	  can	  be	   changed	   in	   many	   different	   ways,	   for	   example	   by	   environmental	   factors	   such	   as	  ultraviolet	   radiation	   or	   chemical	   mutagens	   as	   well	   as	   by	   random	   mistakes	   in	   DNA	  replication.	  To	  counteract	   these	   tens	  of	   thousands	  DNA	  damages	   that	  are	  produced	  each	  day	   inside	   every	   cell,	   all	   organisms	   have	   developed	   repair	   processes.[6]	   However	   any	  resulting	  damage,	   if	   not	   repaired	   correctly,	  may	   lead	   to	   severe	   consequences	   that	   range	  from	  the	  induction	  of	  cell	  death	  by	  apoptosis	  (programmed	  cell	  death)	  or	  senescence	  (cell	  growth	  arrest)	  to	  the	  emergence	  of	  cancer	  (Figure	  1).	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While	   DNA	   damage	   is	   a	   key	   factor	   in	   the	   origin	   of	   cancer	   cells,	   inhibition	   of	   DNA	  replication	  by	  DNA-­‐damaging	  agents	   is	  used	  as	  part	  of	  clinical	   treatments	  to	  prevent	  the	  cancer	   cells	   from	   reproducing.	   In	   fact,	   many	   important	   chemotherapeutic	   drugs	   act	   by	  their	   ability	   to	   generate	   DNA	   lesions.[8]	   Among	   them,	   the	   DNA	   alkylators	  were	   the	   first	  anticancer	   therapeutics	   and	   they	   remain	   the	   most	   effective	   agents	   for	   cancer	  management.[9]	  	  	  	  





Figure	  2:	  Chemical	  structures	  of	  the	  warfare	  agent	  sulphur	  mustard	  and	  therapeutically	  useful	  nitrogen	  mustard	  derivatives.	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1.1.2	  Chemistry	  of	  Nitrogen	  Mustards	  	  	  Nitrogen	   mustards	   are	   classified	   as	   alkylating	   agents,	   as	   studies	   of	   the	   reaction	  mechanisms	  indicated	  that	  the	  cytotoxic	  effects	  were	  due	  to	  alkylation.[14,16]	  An	  alkylating	  agent	   is	   defined	   as	   a	   substance	   that	   can	   replace	   a	   hydrogen	   atom	   with	   an	   alkyl	   group	  under	   physiological	   conditions	   (aqueous	   solution,	   pH	   7.4,	   37	  °C).[17]	   In	   particular,	   these	  alkylating	   reactions	   take	   place	   with	   important	   intracellular	   biomolecules,	   while	   DNA	  represents	  the	  principal	  target	  for	  the	  cytotoxic	  effect.	  	  The	  general	  mechanism	  of	  action	  of	  the	  nitrogen	  mustards	  (A)	  involves	  the	  formation	  of	  a	  highly	  reactive	  aziridinium	  ion	  (B,	  Figure	  3).[18]	  This	  electrophilic	  intermediate	  species	  (B)	  can	   react	  with	   susceptible	   nucleophilic	   sites	  within	   DNA	   to	   form	   covalent	   DNA	   adducts	  (see	   box	   in	   Figure	   3).[19]	   In	   this	   regard,	   nitrogen	   mustards	   display	   a	   certain	   degree	   of	  target	   selectivity	   in	   their	   reactions	  with	   DNA	   bases.	   It	   was	   found	   that	   the	  most	   readily	  alkylated	  site	  on	  DNA	  is	  the	  N-­‐7	  position	  of	  guanine	  (C).[20]	  In	  addition	  to	  forming	  guanine	  monoadducts	  (D),	  the	  second	  chloroethyl	  side	  chain	  of	  the	  nitrogen	  mustard	  molecule	  can	  undergo	   the	  same	  activation	  process,	   followed	  by	  a	  nucleophilic	  attack	  on	   the	  generated	  alkylating	  moiety.	  Thus,	  these	  bifunctional	  agents	  are	  able	  to	  produce	  covalent	  biadducts	  (E)	  with	  guanine	  residues	  on	  both	  strands	  of	  DNA,	  affording	   interstrand	  cross-­‐links.[20,21]	  As	   a	   consequence	   of	   DNA	   cross-­‐linking	   and	   the	   resulting	   structural	   distortions	   of	   the	  double	  helix,	  DNA	  strand	  separation	  is	  prevented	  leading	  to	  inhibition	  of	  DNA	  replication	  and	  transcription.[22]	  	  	  
	  	  
	  
Figure	   3:	   Mechanism	   of	   DNA	   alkylation	   by	   nitrogen	  mustards	   and	   formation	   of	   DNA	   adducts.	   Cross-­‐linking	   can	  occur	  either	  within	  a	  DNA	  strand	   (intrastrand)	  or	  between	   two	  complementary	   strands	  of	  DNA	  (interstrand).	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1.2	  Drug	  Development	  from	  Natural	  Products	  	  
	  Historically,	  nature	  has	  been	  ever	  since	  the	  source	  and	  inspiration	  for	  traditional	  remedies	  and	  novel	  therapeutic	  agents.	  However,	  only	  a	  small	  percentage	  of	  the	  world’s	  biodiversity	  has	   been	   evaluated	   for	   potential	   pharmaceutical	   purposes.[27]	   It	   is	   apparent	   that	   many	  more	  valuable	  natural	  compounds	  with	  therapeutic	  potential	  are	  still	  awaiting	  discovery.	  Indeed,	  natural	  products	  continue	  to	  play	  a	  very	  significant	  role	  in	  modern	  drug	  discovery	  and	  development.[28]	  It	  has	  been	  estimated	  that	  approximately	  50%	  of	  the	  newly	  approved	  drugs	  between	  the	  years	  2000	  and	  2010	  were	  derived	  from	  natural	  products.[29]	  	  Generally,	   the	   term	   natural	   product	   refers	   to	   organic	   compounds	   that	   are	   produced	   by	  living	  systems	  such	  as	  plants,	  microorganisms	  and	  marine	  organisms	  and	  is	  usually	  used	  synonymously	  with	  secondary	  metabolite.[30]	  Whereas	  primary	  metabolites	  (nucleic	  acids,	  proteins,	   lipids,	   carbohydrates)	   are	   ubiquitous	   and	   essential	   to	   the	   organismal	   function,	  secondary	   metabolites	   are	   limited	   in	   their	   biological	   distribution	   and	   are	   not	   directly	  involved	  in	  the	  maintenance	  and	  development	  of	  an	  organism.	  Most	  often,	  the	  latter	  have	  different	   ecological	   roles,	   notably	   in	   specific	   defence	   mechanisms	   against	   herbivores,	  microbes,	  viruses	  or	  competing	  plants.[31]	  Due	   to	   their	   known	   potential	   beneficial	   effects	   on	   human	   health,	   natural	   products	   have	  attracted	   sustained	   interest	   of	   scientists	   in	   this	   field,	   particularly	  with	   regard	   to	   cancer	  therapy.	  It	  is	  significant	  that	  today	  more	  than	  60%	  of	  the	  anticancer	  agents	  in	  current	  use	  or	  clinical	  trials	  are	  of	  natural	  product	  origin.[32]	  Probably	  the	  most	  prominent	  example	  of	  a	   plant-­‐based	   remarkably	   effective	   antitumour	   drug	   is	   paclitaxel	   (Taxol®),	   a	   highly	  functionalized	   diterpenoid,	   originally	   isolated	   from	   the	   bark	   of	   Pacific	   yew	   (Taxus	  
brevifolia).[33]	  In	  spite	  of	  its	  great	  success	  in	  the	  treatment	  of	  advanced	  breast	  and	  ovarian	  cancer,	  paclitaxel	  was	  a	  subject	  of	  a	  major	  supply	  issue.[34]	  The	  problem	  of	  limited	  natural	  paclitaxel	   source	  was	   overcome	   by	   alternative	   production	  methods	   such	   as	   cell	   culture,	  semi-­‐synthesis	   and	  biosynthesis	   in	  microorganisms.[35]	   As	   a	  matter	   of	   fact,	   the	   adequate	  resupply	   of	   natural	   products	   is	   a	   continuing	   challenge	   faced	   in	   drug	   discovery	   and	  development.[36]	   While	   efficient	   total	   synthesis	   can	   provide	   a	   potential	   route	   for	   bulk	  production	  of	  bioactive	  naturally	  occurring	  compounds,	  it	  can	  turn	  out	  to	  be	  an	  expensive	  and	   complicated	   procedure.	   Therefore,	   natural	   molecular	   scaffolds	   serve	   often	   as	   new	  structural	   leads	   for	   the	   design	   of	   simpler	   analogues	   with	   similar	   or	   optimised	  pharmacological	  properties.	  Also	   in	  case	  of	   the	  unique	  taxane	  skeleton,	  hundreds	  of	  new	  derivatives	   were	   synthesised	   and	   several	   drug	   candidates	   with	   improved	   therapeutic	  indices	  are	  currently	  in	  clinical	  trials.[37]	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1.2.1	  The	  Piperidine	  Mustard	  Pharmacophore	  
	  As	   highlighted	   in	   the	   previous	   section,	   rational	   drug	   design	   and	   syntheses	   of	   natural	  product-­‐based	   analogues	   represent	   a	   key	   component	  with	   regard	   to	   the	   drug	   discovery	  process.	   From	   structural	   modifications	   of	   natural	   lead	   compounds,	   it	   is	   possible	   to	  determine	   the	   molecular	   features	   that	   are	   necessary	   for	   activity,	   the	   so-­‐called	  pharmacophore.[38]	   One	   approach	   to	   improve	   the	   therapeutic	   efficacy	   of	   conventional	  anticancer	   drugs	   is	   by	   utilising	   the	   pharmacophore	   moiety	   as	   part	   of	   new	   bioactive	  molecules.	   Structural	   modifications	   might	   eventually	   lead	   to	   more	   suitable	   drug	  candidates	  with	   improved	  chemical	   stability	  and	  optimised	  side	  effect	  profiles.	   In	   recent	  years,	   a	   vast	   range	   of	   hybrid	   compounds	   incorporating	   the	   nitrogen	  mustard	   unit	   have	  been	  synthesised	  and	  tested	  to	  assess	  their	  potential	  as	  antitumour	  agents.[39]	  	  
	  
Figure	  5:	  (A)	  Chemical	  structures	  of	  the	  antitumour	  antibiotics	  593A,	  azinomycin	  A	  and	  azinomycin	  B.	  (B)	   Synthetic	   analogue	   of	   the	   azinomycins	   incorporating	   a	   3-­‐chloropiperiridine	   ring[46]	   as	   well	   as	   an	  example	  for	  an	  intercalator–alkylator	  conjugate[48]	  with	  piperidine	  mustard	  functionalities.	  	  	  Interestingly,	   since	   nitrogen	   mustards	   are	   not	   found	   naturally	   in	   environment,	   the	  antibiotic	   593A	   (NSC-­‐135758,	   Figure	   5A)	   represents	   the	   first	   mustard-­‐related	   natural	  product	   isolated	   in	   1970	   from	   the	   soil	   organism	   Streptomyces	   griseoluteus.[40]	   The	  antibiotic	  is	  characterised	  by	  a	  unique	  3-­‐chloropiperdine	  ring	  that	  resembles	  the	  structure	  of	  the	  synthetic	  nitrogen	  mustard	  and	  therefore	  is	  supposed	  to	  have	  a	  similar	  mechanism	  of	  alkylation.[41]	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The	  piperazinedione	  593A	  displays	  high	  antineoplastic	  and	  antitumour	  activity,	  however,	  its	   potential	   use	   in	   chemotherapy	   was	   limited	   by	   its	   strong	   myelosuppressive	   effect	  (decrease	  in	  blood	  cell	  production).[42,43]	  In	  addition,	  the	  compound	  represents	  a	  synthetic	  challenge.	  To	  date,	   only	  one	   completed	   total	   synthesis	  has	  been	   reported.[44]	  As	  a	   result,	  the	   strong	   initial	   interest	   in	   593A	   has	   been	   greatly	   diminished	   and	   over	   the	   last	   few	  decades	  no	  further	  research	  studies	  have	  been	  published	  on	  this	  compound.	  Though,	  the	  piperidine	  mustard	  pharmacophore	  has	  been	  used	  as	  alkylating	  moiety	  in	  the	  synthesis	  of	  new	  potential	  anticancer	  agents.[45]	  As	  an	  example,	  Searchey	  and	  co-­‐workers	  replaced	  the	  densely	   functionalised	   DNA-­‐alkylating	   aziridine	   fragment	   of	   the	   antitumour	   antibiotics	  azinomycin	  A	   and	  B	  with	   a	  more	   stable,	   therapeutically	   viable	   3-­‐chloropiperidine	   entity	  (Figure	   5).[46,47]	   In	   an	   attempt	   to	   overcome	   drug	   resistance,	   piperidine-­‐based	   mustards	  have	   also	   been	   incorporated	   in	   the	   design	   of	   DNA	   intercalator–alkylator	   conjugates	  (Figure	  5B).[48]	  These	  DNA-­‐affinic	  alkylating	  anthraquinones	  showed	  a	  broad	  spectrum	  of	  antitumour	   activity.	   Thus,	   the	   piperidine	   mustard	   pharmacophore	   has	   proven	   to	   be	   a	  promising	  structural	  scaffold	  in	  the	  search	  of	  more	  suitable	  anticancer	  drug	  candidates.	  	  	  	  
1.2.2	  Molecular	  Scaffolds	  for	  DNA	  Recognition	  
	  Nature	  offers	  a	  diverse	  range	  of	  structural	  motifs	   for	  molecular	  recognition	  of	  DNA	  (e.g.,	  intercalators,	   polypyrroles,	   polyimidazoles).[49]	   In	   fact,	   natural	   products	   have	   revealed	  interesting	   DNA-­‐binding	   mechanisms	   which	   produce	   favourable	   pharmacological	  effects.[50]	   These	   molecular	   recognition	   processes	   involve	   electrostatic	   binding,	  interactions	  in	  the	  major	  and	  minor	  grooves	  of	  DNA	  as	  well	  as	  intercalation	  between	  the	  base	   pairs	   of	   the	   double	   helix.[51]	   Such	   noncovalent	   association	   of	   small	  molecules	  with	  nucleic	  acids	  can	  distort	  the	  regular	  structure	  of	  DNA	  and	  interfere	  with	  essential	  cellular	  functions.	  The	  ability	  of	   various	  natural	   compounds	   to	   interact	  with	  DNA	  via	   the	  above-­‐mentioned	  binding	  modes	  is	  associated	  with	  their	  biological	  activities.	  For	  instance,	  it	  has	  been	  found	  that	  the	  naphthoate	  group	  of	  the	  azinomycin	  antibiotics	  (compare	  Figure	  5A)	  plays	  a	  crucial	  role	  in	  sequence	  selective	  DNA-­‐binding	  affinity	  and	  cytotoxic	  activity.[52]	  Of	  particular	  interest	  in	  the	  development	  of	  antitumour	  drugs	  are	  the	  DNA	  intercalators.	  This	  clinically	   important	   class	   of	   reversible	  DNA-­‐binding	   agents	   is	   discussed	   in	   the	   following	  section	  of	  this	  chapter.	  	  	  
1.2.2.1	  DNA	  Intercalators	  	  
	  	  A	  variety	  of	  natural	  and	  synthetic	  products	  bind	  to	  DNA	  by	   intercalating	   into	   the	  double	  helix	  (Figure	  6).[53]	  DNA	  intercalators	  are	  mostly	  polycyclic,	  aromatic	  and	  planar	  molecules	  that	  are	   capable	  of	   inserting	  between	  DNA	  base	  pairs	  by	  means	  of	  noncovalent	   stacking	  interactions.	   As	   a	   result,	   intercalation	   causes	   conformational	   alterations	   in	   the	   helix	  geometry	   and	   local	   unwinding	   at	   the	   site	   of	   binding,	   leading	   to	  DNA	  damage	  which	   can	  trigger	  cytotoxic	  effects.	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Due	  to	  their	  cytotoxic	  actions,	  intercalating	  agents	  have	  been	  widely	  investigated	  for	  their	  potential	   anticancer	   properties.[54]	   Representative	   and	   therapeutically	   interesting	  compounds	  include	  acridines	  and	  anthracyclines	  (Figure	  7).	  The	  DNA-­‐binding	  mechanism	  of	   the	   acridine	   proflavine	   was	   the	   first	   proposed	   model	   of	   intercalation	   described	   by	  Lerman	  in	  1961.[55]	  To	  date,	  thousands	  of	  natural	  and	  synthetic	  acridine	  derivatives	  have	  been	   extensively	   explored	   as	   antitumour	   drugs	   and	   some	   have	   been	   approved	   for	  chemotherapy.[56]	  	  	  
 





Figure	  7.	  Structures	  of	  representative	  acridine	  and	  anthracycline	  DNA	  intercalators.	  	  The	   development	   of	   such	   potent	   analogues	   with	   promising	   therapeutic	   properties	   has	  motivated	   the	  search	   for	  new	  compounds	  based	  on	   these	   intercalating	  pharmacophores.	  In	  fact,	   the	  acridine	  and	  anthraquinone	  scaffolds	  serve	  as	  privileged	  structural	  motifs	  for	  DNA-­‐targeted	  drug	  design.[48,64]	  	  	  	  	  	  	  
1.3	  Bis-­‐3-­‐chloropiperidines	  as	  DNA	  Alkylating	  Agents	  	  
	  
1.3.1	  Motivation,	  Aim	  and	  Objectives	  	  The	  antibiotic	  593A	  can	  be	   considered	  as	   a	  naturally	  occurring	  piperazinedione-­‐bridged	  bis-­‐3-­‐chloropiperidine	   (compare	   Figure	   8).	   Studies	   on	   the	   antitumour	   activity	   of	   this	  compound	   indicate	   that	   the	   antibiotic	   acts	   as	   an	   alkylating	   agent	   in	   inhibiting	   DNA	  synthesis	  and	  cell	  proliferation	  of	  tumour	  cells.[42]	  However,	  the	  exact	  mechanism	  of	  action	  is	  still	  unknown	  and	  remains	  to	  be	  elucidated;	  unfortunately,	  the	  difficulties	  encountered	  in	   the	   chemical	   synthesis	   of	   this	   natural	   product	   represent	   a	   challenge	   for	   mechanistic	  investigations.	  In	   this	   context,	   synthetic	   studies[65,66]	   in	   our	   group	   towards	   the	   preparation	   of	   3-­‐chloropiperidines	   have	   led	   to	   our	   research	   interest	   in	   the	   synthesis	   of	   structurally	  simplified	  analogues	  of	  antibiotic	  593A.	  Based	  on	  our	  promising	  preliminary	  results[67,68],	  the	  present	  research	  project	   focuses	  on	  the	  design	  and	  biological	  evaluation	  of	  nitrogen-­‐linked	  bis-­‐3-­‐chloropiperidines	  with	   the	  overall	  aim	  to	  provide	   insight	   into	   the	  molecular	  mode	  of	  action	  of	  the	  related	  antibiotic.	  	  The	   first	   part	   of	   the	   work	   is	   dedicated	   to	   the	   synthesis	   of	   a	   series	   of	   bis-­‐3-­‐chloropiperidines	  with	  various	   linker	  structures	  as	  proof-­‐of-­‐principle	  derivatives	  (Figure	  8).	   To	   establish	   structure–activity	   relationships,	   linkers	   are	   defined	   in	   terms	   of	   the	  following	   structural	   features:	   linker	   length,	   conformation	   (i.e.,	   flexible,	   rigid)	   and	   the	  chemical	   composition	   of	   a	   side-­‐chain	   attached	   to	   the	   linker	   (e.g.,	   ester	   and	   aromatic	  functional	  groups).	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In	   the	   second	   part,	   mechanistic	   studies	   on	   the	   reaction	   of	   bis-­‐3-­‐chloropiperidines	   with	  double-­‐stranded	  DNA	  are	  performed	  using	  gel	  electrophoresis	  methods.	  The	  synthesised	  compounds	  are	  investigated	  for	  their	  DNA	  alkylation	  properties	  in	  order	  to	  determine	  the	  effect	  of	  linker	  structure	  on	  activity.	  	  	  
 
Figure	   8:	   General	   structure	   of	   nitrogen-­‐linked	   bis-­‐3-­‐chloropiperidines	   as	   simplified	   analogues	   of	  antibiotic	  593A.	  Linker	  length,	  conformation	  (flexibility/rigidity)	  and	  composition	  (side-­‐chain	  functional	  groups)	  is	  systemically	  varied	  to	  explore	  structure–activity	  relationships.	  	  	  	  









Scheme	   1:	  General	   strategy	   for	   the	   bidirectional	   synthesis	   of	   nitrogen-­‐linked	   bis-­‐3-­‐chloropiperidines	  (D).	   The	   target	   compounds	   D	   were	   obtained	   as	   inseparable	   diastereomeric	   mixtures.	   [a]	   Oil	   bath	  temperature.	  	  
	  Preliminary	   work	   in	   our	   group	   initiated	   with	   the	   design	   of	   a	   series	   of	   derivatives	  incorporating	   flexible	   linkers	  with	  alkyl	   chain	   lengths	  ranging	   from	  3–6	  methylene	  units	  between	  the	  alkylating	  moieties.[67]	  Additionally,	  we	  chose	  to	  investigate	  conformationally	  restricted	  and	  rigid	  linkers	  by	  introducing	  a	  bridging	  cyclohexyl	  as	  well	  as	  aromatic	  linker	  structures.[71]	   In	   continuation	  of	   our	  previous	   research	   (see	  Chapter	  2)	  on	   the	   impact	  of	  flexible	   and	   rigid	   linkers	   on	   DNA	   alkylating	   activity,	  we	  wanted	   to	   explore	   the	   effect	   of	  different	  aromatic	  motifs	   attached	   to	   the	   carboxylic	  acid	   side	   chain	  of	   a	   L-­‐lysine	   linkage.	  Thus,	   a	   series	   of	   lysine	   ester	   bridged	   bis-­‐3-­‐chloropiperidines	   was	   prepared,	   enabling	  comparative	  studies	  on	  the	  structure‒activity	  relationship	  (see	  Chapter	  3	  as	  well	  as	  Table	  1).	  The	  results	  of	  these	  studies	  are	  discussed	  below.	  	  
	  
	  
1.3.3	  DNA	  Alkylation	  by	  3-­‐Chloropiperidines	  	  Generally,	   the	   reaction	   of	   3-­‐chloropiperidines	   (A)	   with	   nucleophiles	   has	   been	   found	   to	  proceed	  through	  the	  formation	  of	  a	  bicyclic	  aziridinium	  ion	  intermediate	  (B,	  Figure	  9).[72]	  We	   were	   able	   to	   verify	   the	   rapid	   generation	   of	   B	   by	   electrospray	   ionisation	   mass	  spectrometry	   (ESI-­‐MS;	   see	   Chapter	   3).	   This	   electrophilic	   species	   (B)	   can	   subsequently	  alkylate	  nucleophilic	  centers	  in	  DNA	  to	  give	  five-­‐	  (C)	  and	  six-­‐membered	  (D)	  ring	  products.	  (Figure	   9;	   see	   also	   Chapter	   2).[48]	   The	   identity	   of	   the	   resulting	   DNA	   alkylation	   products	  depend	  on	  the	  steric	  effects	  of	  the	  residue	  R	  and	  the	  attacking	  nucleophile.	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Figure	   9:	   General	   alkylation	   mechanism	   of	   3-­‐chloropiperidines	   (A)	   via	   a	   bicyclic	   aziridinium	   ion	  intermediate	  (B).	   In	  a	  subsequent	  step,	   the	  electrophilic	  and	  highly	  reactive	  species	  (B)	  can	  be	  readily	  attacked	  by	  nucleophilic	   sites	  within	   the	  DNA	  double	   helix	   to	   form	   covalent	  DNA–pyrrolidine	   (C)	   and	  DNA–piperidine	  (D)	  adducts.	  	  The	  main	  nucleophilic	  targets	  of	  alkylating	  agents	  are	  the	  purine	  and	  pyrimidine	  bases	  in	  the	  DNA	  molecule.	  Here,	   the	  preferred	  site	  of	  DNA	  attack	  depends	  on	  the	  accessibility	  of	  the	  reactive	  alkylating	  species	  to	  the	  DNA	  base	   in	  question	  and	  thus	  varies	  by	  agent	  and	  suitable	   chemical	   environment.	   As	   mentioned	   before,	   nitrogen	   mustards	   bind	   pre-­‐dominantly	   to	   the	   highly	   nucleophilic	   nitrogen	   atom	   on	   position	   7	   of	   the	   guanine	   ring	  system	  (see	  Section	  1.1.2,	  Figure	  3).[73]	  One	  effect	  of	   guanine	  alkylation	   is	   an	   increase	   in	  the	   electrophilicity	   of	   neighboring	   positions,	  which	   can	   lead	   to	   hydrolytic	  DNA	   cleavage	  reactions.	   Alternatively,	   alkylation	   can	   destabilise	   the	   nucleobases,	   followed	   by	  deglycosylation	  and	  subsequent	  DNA	  strand	  scission	  (compare	  Figure	  4).	  	  	  	  
1.3.4	  DNA	  Cleavage	  Activity	  of	  Bis-­‐3-­‐chloropiperidines	  	  In	   our	   studies	   on	   the	   reactivity	   of	   bis-­‐3-­‐chloropiperidines	   towards	   nucleic	   acids	   we	  analysed	  the	  DNA	  alkylating	  activities	  of	  the	  synthesised	  agents	  using	  gel	  electrophoresis	  techniques	   (compare	  Chapters	  2‒4).	   Consistent	  with	  our	  proposed	  mechanism	  of	   action	  for	  3-­‐chloropiperidines	  presented	  in	  the	  previous	  section,	  we	  could	  demonstrate	  that	  the	  examined	   compounds	   alkylate	   and	   cleave	   double-­‐stranded	   DNA	   very	   efficiently.	  Furthermore,	  DNA-­‐sequencing	  experiments	   identified	  guanine	  bases	  as	   the	  predominant	  site	   of	   alkylation	   by	   bis-­‐3-­‐chloropiperidines.	   These	   results	   are	   described	   in	  more	   detail	  below.	  The	  ability	  of	   the	  synthesised	  compounds	  to	  cleave	  double-­‐stranded	  DNA	  was	  studied	   in	  simple	   DNA	   plasmid	   system	   under	   physiological	   conditions	   (aqueous	   buffer	   at	   pH	   7.4,	  37	  °C).	   Supercoiled	  DNA	   (pAT153	   and	   pBR322,	   respectively)	  was	   incubated	   for	   3	   hours	  with	  increasing	  concentrations	  (0.5,	  5,	  50	  µM)	  of	  appropriate	  agents.	  DNA	  strand	  cleavage	  can	  be	  detected	  by	  assessing	  the	  conversion	  from	  the	  naturally	  occurring	  supercoiled	  (SC)	  to	   the	   nicked	   open	   circular	   (OC)	   and	   linear	   form	   (L)	   of	   plasmid	   DNA	   by	   means	   of	   gel	  electrophoresis	  (Figure	  10).[74]	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These	  various	  DNA	  conformations	  migrate	  through	  the	  gel	  at	  different	  rates,	  depending	  on	  their	   size	   and	   charge	   as	  well	   as	   on	   the	   characteristics	   of	   the	   gel	   (i.e.,	   concentration,	   gel	  type)	   and	   electrophoretic	   conditions	   (e.g.,	   buffer	   system,	   applied	   voltage,	   duration	   of	  electrophoresis).[75]	   Generally,	   supercoiled	   DNA	   shows	   the	   highest	   electrophoretic	  mobility	  due	  to	  its	  compact	  conformation	  (compare	  band	  L,	  Figure	  10B).	  If	  one	  DNA	  strand	  is	  cleaved	  (nicked),	  the	  supercoiled	  plasmid	  will	  relax	  into	  the	  open	  circular	  form,	  which	  can	   be	  monitored	   by	   the	   appearance	   of	   a	   slower	  migrating	   gel	   band	   (compare	   lane	  OC,	  Figure	  10B).	  Double-­‐strand	  cleavage	  will	  generate	  a	  linear	  DNA	  molecule	  that	  usually	  runs	  between	   the	   supercoiled	   and	  open	   circular	   forms	   (see	  Figure	  10B,	   compare	  bands	   SC,	   L	  and	  OC).	  	  	  
Figure	   10:	   Schematics	   of	   plasmid	   DNA	   conformations.	   (A)	   DNA	   cleavage	   results	   in	   the	   conversion	   of	  supercoiled	  plasmid	  to	  the	  nicked	  open	  circular	  (single-­‐strand	  break,	  SSB)	  or	  linear	  form	  (double-­‐strand	  break,	  DSB).	  (B)	  Illustration	  of	  an	  electrophoresis	  gel	  showing	  the	  relative	  positions	  (in	  terms	  of	  relative	  migration	   rates)	   of	   the	   different	   plasmid	   DNA	   forms,	   visible	   as	   discrete	   bands.	   The	   typical	   order	   of	  electrophoretic	  mobility	  in	  agarose	  gels,	  from	  fastest	  to	  slowest,	  is	  as	  follows:	  supercoiled	  (SC)	  plasmid	  ˃	  linear	  (L)	  DNA	  ˃	  open	  circular	  (OC)	  form.	  	  	  In	   an	   initial	   study[67],	   the	   agarose	   gel	   electrophoresis	   patterns	   for	   the	   cleavage	   of	  supercoiled	  plasmid	  DNA	  pAT153	  by	  bis-­‐3-­‐chloropiperidines	   suggested	   the	   induction	   of	  double-­‐strand	  breaks.	  Optimisation	  of	  the	  agarose	  concentration	  (1%	  agarose	  gel	  instead	  of	   0.8%)	   and	   running	   buffer	   conditions	   (1	   ×	   Tris-­‐borate-­‐EDTA	   instead	   of	   1	   ×	   Tris-­‐phosphate-­‐EDTA	   buffer)	   resulted	   in	   an	   improved	   separation	   of	   DNA	   fragments.	   Under	  these	   optimised	   electrophoretic	   conditions,	   the	   investigated	   compounds	   were	   found	   to	  nick	  supercoiled	  DNA	  to	  yield	  single-­‐strand	  breaks,	  rather	  than	  cleavage	  of	  both	  strands.	  Significantly,	   the	   findings	   from	   our	   current	   studies	   reveal	   that	   bis-­‐3-­‐chloropiperidines	  exhibit	  effective	  DNA	  alkylating	  properties	  and	  promote	  guanine-­‐specific	  cleavage	  through	  a	  DNA	  nicking	  mechanism	  (see	  Chapters	  2‒4).	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In	   an	   attempt	   to	   estimate	   the	   relative	   cleavage	   activities	   of	   all	   bis-­‐3-­‐chloropiperidines	  tested,	  the	  effective	  concentrations	  causing	  50%	  of	  the	  maximal	  DNA	  nicking	  (EC50)	  were	  determined	   by	   measuring	   the	   ability	   of	   the	   agents	   to	   convert	   supercoiled	   DNA	   into	   its	  open	  circular	   form.	  Table	  1	  gives	  a	  summary	  of	   the	  approximate	  EC50	  values	  (these	  data	  can	   be	   understood	   as	   visualization	   of	   results	   from	   the	   DNA	   cleavage	   assays;	   compare	  Chapters	  2‒4).	  	  
	  
	  
Table	   1:	   Approximate	   half	   maximal	   effective	   concentration	   (EC50)	   data	   for	   all	   investigated	   bis-­‐3-­‐chloropiperidines.	  	  EC50	  values	  were	  calculated	  by	  comparing	  the	  intensity	  of	  supercoiled	  gel	  bands	  from	  the	  DNA	   cleavage	   assays	   (compare	  Chapters	  2‒4)	  with	   the	   value	  of	  DNA	   control	   lane	   as	   a	   function	  of	  compound	   concentration.	   Band	   intensities	   were	   quantified	   using	   GeneTools™	   software	   from	  PerkinElmer®.	  [a]	  EC50	  value	  was	  not	  determinable	  due	  to	  DNA	  fragmentation.	  [b]	  Unpublished	  data.[71]	  [c]	  Activity	  involves	  most	  likely	  DNA	  intercalation	  (see	  Chapter	  4).	  	  Our	   data	   indicate	   that	   the	   linker	   length	   has	   no	   apparent	   effect	   on	   DNA	   alkylating	  properties,	   whereas	   the	   flexibility	   of	   the	   linker	   region	   appears	   to	   be	   a	   key	   structural	  feature	   for	   bis-­‐3-­‐chloropiperidines	  with	  high	   activity	   (EC50	   <	   1	   µM).	  The	   introduction	  of	  aromatic	  groups	  or	  an	  ester	   functionality	   into	   the	   linker	   structure,	   in	  general,	   leads	   to	  a	  decrease	  in	  DNA	  cleavage	  activity	  (compare	  Table	  1).	  	  Remarkably,	   although	   the	   naphthoate	   derivatives	   appear	   to	   have	   no	   apparent	   DNA	  alkylating	   capabilities	   (EC50	   >	   50	  µM),	   our	   studies	   clearly	   show	   that	   these	   compounds	  interact	   with	   DNA	   (see	   Chapter	   3).	   These	   results	   support	   our	   assumption	   that	   the	  incorporation	  of	  	  DNA-­‐affinic	  moieties	  (such	  as	  naphthalene-­‐type	  chromophores)	  can	  be	  a	  valuable	  concept	  for	  designing	  DNA-­‐targeted	  agents.	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1.4	  Summary	  and	  Future	  Directions	  	  	  	  In	   the	   present	   research	   work,	   a	   series	   of	   nitrogen-­‐linked	   bis-­‐3-­‐chloropiperidines	   was	  synthesised	   as	   structurally	   simplified	   analogues	   of	   the	   antitumour	   antibiotic	   593A	  (compare	   Figure	   8;	   all	   compounds	   discussed	   herein	   are	   summarised	   in	   Table	   1).	   The	  ability	  of	   these	  nitrogen	  mustard-­‐type	  compounds	   to	  alkylate	  DNA	  was	  studied	  with	   the	  aim	  to	  gain	  a	  better	  understanding	  of	  their	  molecular	  mechanism	  of	  action	  (see	  Chapters	  2‒4).	  Our	  approach	  was	  to	  survey	  the	  effect	  of	  various	  linker	  structures	  on	  DNA	  alkylation	  activity	  using	  electrophoretic	  methods	  for	  the	  detection	  of	  agent-­‐induced	  DNA	  cleavage.	  	  Thus,	   we	   have	   constructed	   a	   small	   library	   of	   bis-­‐3-­‐chloropiperidine	   derivatives	   with	  flexible	   alkyl,	   a	   conformationally	   constrained	   cyclohexyl,	   rigid	   aromatic	   or	   lysine	   ester	  linkers.	   The	   synthesis	   of	   these	   compounds	  was	   successfully	   carried	   out	   by	  means	   of	   an	  efficient	   bidirectional	   procedure	   developed	   in	   our	   laboratory.	   The	   key	   steps	   of	   the	  reaction	  sequence	  are	  the	  reductive	  amination	  of	   the	  respective	  diamine	   linker	  with	  2,2-­‐dimethylpent-­‐4-­‐enal,	  followed	  by	  chlorination	  and	  subsequent	  iodide-­‐catalysed	  cyclisation	  of	   the	   unsaturated	   precursor	   to	   yield	   the	   corresponding	   desired	   bis-­‐3-­‐chloropiperidine	  (compare	  Scheme	  1).	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The	   synthesised	   compounds	   were	   evaluated	   in	   vitro	   for	   their	   alkylating	   properties	  towards	  double-­‐stranded	  DNA	  (supercoiled	  plasmids	  pAT153	  and	  pBR322	  as	  well	  as	  a	  22-­‐mer	   oligonucleotide).	   For	   this	   purpose	   DNA	   cleavage	   assays	   were	   performed	   (under	  physiological	  conditions	  at	  pH	  7.4	  and	  37	  °C),	  allowing	  direct	  comparison	  of	   the	  relative	  efficiencies	  of	  DNA	  alkylation	  (see	  Table	  1).	  The	  gel	  electrophoresis	  results	  demonstrated	  that	   the	   examined	   bis-­‐3-­‐chloropiperidines	   cleave	   DNA	   in	   a	   concentration-­‐dependant	  manner	   (from	   0.5	   to	   50	   µM)	   via	   a	   DNA	   nicking	   mechanism,	   generating	   single-­‐strand	  breaks.	  	  Notably,	   we	   found	   that	   compounds	   containing	   flexible	   alkyl	   chain	   linkers	   exhibit	  significant	  DNA	  cleavage	  activities	   (EC50	  <	  1	  µM),	  whereby	  chain	   length	  variation	  has	  no	  apparent	  influence.	  On	  the	  other	  hand,	  aromatic	  linkers	  are	  able	  to	  reduce	  the	  reactivity	  of	  bis-­‐3-­‐chloropiperidines	  with	  DNA,	   indicating	   that	   conformational	   flexibility	   of	   the	   linker	  region	   is	  an	   important	   structural	   feature	   for	   cleavage	  efficiency	   (compare	  Chapter	  2).	   In	  addition,	  the	  introduction	  of	  an	  ester	  functionality	  to	  the	  side	  chain	  of	  the	  linker	  (i.e.,	  xylyl	  ester,	   lysine	   ester)	   results	   in	   diminished	   activity,	  most	   likely	   depending	   on	   the	   size	   and	  nature	  of	   the	  ester.	   In	  general,	   activities	  decrease	  with	   increasing	  steric	  bulkiness	  of	   the	  ester	  unit	   (i.e.,	  methyl	  group,	   simple	  phenyl	  derivatives,	  naphthalene	  and	  anthraquinone	  chromophores)	  in	  the	  lysine	  linker	  (see	  Chapters	  3	  and	  4).	  An	  interesting	  exception	  to	  this	  observation	   is	   the	   anthraquinone	   conjugate	   that,	   despite	   its	   bulky	   shape,	   displays	  considerable	   activity	   (EC50	   =	   2	   µM).	  Our	  data	   suggest	   a	   possible	   intercalative	   process	   in	  which	   the	   anthraquinone	   component	   inserts	   itself	   between	   the	   base	   pairs	   of	   the	   DNA	  double	   helix	   (compare	  Chapter	   4).	  However,	   this	  mode	  of	   action	   remains	   to	   be	   clarified	  directly	  by	  appropriate	  intercalation	  experiments.	  Remarkably,	  although	  compounds	  with	  a	  naphthoate	  moiety	  appear	  to	  be	  inactive	  under	  the	  chosen	  incubation	  conditions	  (EC50	  >	  50	  µM),	  we	  have	  ascertained	  that	   these	  agents	  are	  able	   to	   interact	  with	  double-­‐stranded	  DNA	   (see	   Chapter	   3).	   These	   findings	   indicate	   that	   such	   DNA-­‐affinic	   chromophores	   can	  serve	   as	   DNA-­‐recognizing	   structural	   elements	   that	   may	   contribute	   favourably	   to	   DNA-­‐binding.	  	  Furthermore,	   we	   analysed	   the	   alkylation	   sites	   of	   bis-­‐3-­‐chloropiperidines	   by	   DNA	  sequencing	   gel	   electrophoresis.	   Our	   results	   clearly	   demonstrated	   that	   DNA	   strand	  cleavage	  occurs	   primarily	   at	   guanine	   residues.	   Particularly	   striking	  was	   the	  detection	  of	  DNA	   adducts,	   which	   are	   currently	   being	   investigated	   using	   mass	   spectrometry	   (MS)	  techniques.	  Besides,	  we	  verified	  the	  formation	  of	  the	  reactive	  aziridinium	  ion	  intermediate	  by	  ESI-­‐MS	  (see	  Chapter	  3).	  	  Taken	   together,	   these	   studies	   confirm	   our	   proposed	   mechanism	   of	   action	   (compare	  Section	  1.3.3)	   and	   are	   consistent	  with	   the	   observed	   alkylation	   reactions	   of	   conventional	  nitrogen	  mustards.	   It	   is	  noteworthy	  that	  the	  examined	  bis-­‐3-­‐chloropiperidines	  proved	  to	  be	  more	  efficient	  DNA	  alkylating	  agents	  than	  the	  anticancer	  drug	  chlorambucil.	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At	  present,	  studies	  are	  underway	  to	  evaluate	  the	  synthesised	  compounds	  for	  their	  in	  vitro	  cytotoxic	   effects	   on	   various	   human	   cancer	   cell	   lines	   (e.g.,	   A375,	   HCT-­‐15,	   Bx-­‐PC3,	   2008,	  MCF-­‐7).	  Moreover,	   ongoing	  mechanistic	   investigations	   focus	  on	   identifying	   the	  alkylated	  positions	   in	   guanines	   as	   well	   as	   the	   characterisation	   (by	   means	   of	   MS)	   of	   the	   DNA	  alkylation	   products.	   In	   addition,	   we	   plan	   to	   further	   clarify	   the	   molecular	   mechanism	  underlying	   the	   observed	   interactions	   of	   the	   chromophore	   conjugates	   with	   double-­‐stranded	  DNA.	  Due	  to	  our	  promising	  experimental	  results,	  future	  work	  on	  this	  project	  will	  be	   directed	   towards	   the	   design,	   synthesis	   and	   biological	   examination	   of	   novel	   bis-­‐3-­‐chloropiperidine	  derivatives	  attached	  to	  a	  DNA-­‐affinic	  carrier	  molecule	  (e.g.,	  intercalators,	  polypyrroles	   and	   polyimidazoles).	   This	   approach	   might	   provide	   a	   valuable	   strategy	   to	  enhance	  DNA-­‐binding	  affinity	  and	  specificity	  of	  this	  new	  class	  of	  alkylating	  agents.	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CHAPTER	  2:	  	  
	  
Synthesis	  and	  DNA	  Cleavage	  Activity	  of	  	  
Bis-­‐3-­‐chloropiperidines	  as	  Alkylating	  Agents	  	  
It’s	   all	   about	   G’s!	   An	   elegant	   and	   simple	   bidirectional	   synthetic	   approach	   to	   bis-­‐3-­‐chloropiperdines	  with	  different	  linker	  structures	  is	  reported.	  These	  new	  alkylating	  agents	  generate	  cleavage	  in	  double-­‐stranded	  DNA,	  primarily	  through	  reactions	  towards	  guanine	  sites,	  via	  the	  formation	  of	  electrophilic	  aziridinium	  ion	  intermediates.	  	  	  
	  
	  
Original	  Source:	  Ivonne	   Zuravka,	   Rolf	   Roesmann,	   Alice	   Sosic,	   Wolfgang	  Wende,	   Alfred	   Pingoud,	   Barbara	  Gatto	   and	   Richard	   Göttlich:	   Synthesis	   and	   DNA	   Cleavage	   Activity	   of	   Bis-­‐3-­‐chloro-­‐piperidines	  as	  Alkylating	  Agents;	  ChemMedChem	  2014,	  9,	  2178‒2185.	  Copyright	  ©	  2014	  Wiley-­‐VCH	  Verlag	  GmbH	  &	  Co.	  KGaA,	  Weinheim	  Reproduced	  with	  permission	  of	  the	  copyright	  owner.	  	  
For	  Supporting	  Information	  see	  Appendix	  (pp.	  55).	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CHAPTER	  3:	  	  
	  
Bis-­‐3-­‐chloropiperidines	  Containing	  Bridging	  	  
Lysine	  Linkers:	  Influence	  of	  Side	  Chain	  Structure	  	  
on	  DNA	  Alkylating	  Activity	  	  
Abstract:	  A	  series	  of	  bis-­‐3-­‐chloropiperidines	  containing	  lysine	  linkers	  was	  synthesised	  as	  DNA	  alkylating	  model	  compounds	  by	  using	  a	  bidirectional	  synthetic	  strategy.	  These	  novel	  piperidine	   mustard	   based	   agents	   have	   been	   evaluated	   for	   their	   alkylating	   properties	  towards	  nucleic	  acids	  and	  were	  shown	  to	  alkylate	  and	  cleave	  DNA	  with	  strong	  preference	  for	   guanine	   residues.	  Our	   studies	   reveal	   that	   the	   introduction	  of	   aromatic	   groups	   in	   the	  side	   chain	   of	   the	   lysine	   linker	  has	   an	   impact	   on	  DNA	  alkylating	   activity.	  Analysis	  by	  ESI	  mass	   spectrometry	   enabled	   the	   verification	   of	   the	   reactive	   aziridinium	   ion	   formation.	  Overall,	   the	   results	   confirm	   our	   recently	   proposed	   reaction	   mechanism	   of	   bis-­‐3-­‐chloropiperidines.	  	  	  
	  
Original	  Source:	  Ivonne	   Zuravka,	   Rolf	   Roesmann,	   Alice	   Sosic,	   Richard	   Göttlich	   and	   Barbara	   Gatto:	   Bis-­‐3-­‐chloropiperidines	  Containing	  Bridging	  Lysine	  Linkers:	  Influence	  of	  Side	  Chain	  Structure	  on	  DNA	  Alkylating	  Activity;	  Bioorg.	  Med.	  Chem.	  2015,	  23,	  1241–1250.	  Copyright	  ©	  2015	  Elsevier	  Ltd.	  Reproduced	  with	  permission of	  the	  copyright	  owner.	  	  	  
For	  Supplementary	  Data	  see	  Appendix	  (pp.	  99).	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CHAPTER	  4:	  	  
	  
Synthesis	  and	  Evaluation	  of	  a	  	  
Bis-­‐3-­‐chloropiperidine	  Derivative	  Incorporating	  an	  
Anthraquinone	  Pharmacophore	  	  	  
Combined	  attack	  on	  DNA:	  A	  novel	  bis-­‐3-­‐chloropiperidine	  tethered	  to	  an	  anthraquinone	  moiety	   was	   synthesised	   and	   investigated	   with	   regard	   to	   its	   reactivity	   toward	   double-­‐stranded	  DNA.	  This	  conjugate	  has	  shown	  to	  alkylate	  and	  cleave	  DNA	  	  with	  a	  specificity	  for	  guanine	  bases.	  Our	  results	  suggest	  that	  besides	  DNA	  alkylation	  an	  intercalative	  interaction	  mode	  may	  contribute	  to	  the	  activity	  of	  the	  synthesised	  agent.	  	  	  
	  
	  
Original	  Source:	  Ivonne	  Zuravka,	  Alice	  Sosic,	  Barbara	  Gatto	  and	  Richard	  Göttlich:	  Synthesis	  and	  Evaluation	  of	   a	   Bis-­‐3-­‐chloropiperidine	   Derivative	   Incorporating	   an	   Anthraquinone	   Pharmacophore;	  
2015,	  submitted	  for	  publication.	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Abbreviations	  	  aq.	  	   Aqueous	  BPE	  	   Bisphosphate-­‐EDTA	  buffer	  C	  	   Control	  CA	  	   Chlorambucil	  cat.	  	   Catalytic	  d	  	   Doublet	  DCC	  	   N,N'-­‐Dicyclohexylcarbodiimide	  DCM	  	   Dichloromethane	  DMSO	  	   Dimethyl	  sulfoxide	  DNA	  	   Deoxyribonucleic	  acid	  DSB	  	   Double-­‐strand	  break	  EC50	  	   Half	  maximal	  effective	  concentration	  EDTA	  	   Ethylenediaminetetraacetic	  acid	  e.g.	  	   Exempli	  gratia	  –	  for	  example	  	  equiv.	  	   Equivalent	  ESI-­‐MS	  	   Electrospray	  ionisation	  mass	  spectrometry	  FAM	  	   Carboxyfluorescein	  G	  	   Guanine	  h	  	   Hour(s)	  HOBt	  	   Hydroxybenzotriazole	  HRMS	  	   High-­‐resolution	  mass	  spectrometry	  i.e.	  	   Id	  est	  –	  that	  is	  L	  	   Linear	  DNA	  M	  	   Molar	  m	  	   Multiplet	  NCS	  	   N-­‐Chlorosuccinimide	  NMR	  	   Nuclear	  magnetic	  resonance	  spectroscopy	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OC	  	   Open	  circular	  DNA	  PAGE	   Polyacrylamide	  gel	  electrophoresis	  ppm	  	   parts	  per	  million	  RT	  	   Room	  temperature	  s	  	   Singlet	  satd.	  	   Saturated	  SC	  	   Supercoiled	  DNA	  SSB	  	   Single-­‐strand	  break	  t	  	   Triplet	  TAE	  	   Tris-­‐acetate-­‐EDTA	  buffer	  TBAI	  	   Tetrabutylammonium	  iodide	  TBE	  	   Tris-­‐borate-­‐EDTA	  buffer	  TBME	  	   tert-­‐Butyl	  methyl	  ether	  TFA	  	   Trifluoroacetic	  acid	  TMS	   	  Tetramethylsilane	  Tris	  	   Tris(hydroxymethyl)aminomethane	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  thank	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Mein	  größter	  Dank	  gilt	  meiner	  Familie,	  die	  mir	  während	  all	  dieser	  Zeit	  bedingungslos	  zur	  Seite	  stand.	  Euer	  Vertrauen	  in	  mich	  hat	  mich	  immerzu	  ermutigt	  und	  mir	  die	  Kraft	  gegeben,	  meine	  Ziele	   zu	  erreichen.	   Ich	  danke	  meine	  Eltern,	  Großeltern	  und	  Geschwistern	   für	   ihre	  Unterstützung	   und	   ihr	   entgegengebrachtes	   Verständnis.	   Anni,	   du	   warst	   in	   den	   letzten	  Jahren	   eine	   ganz	  besondere	   Stütze	   für	  mich	  und	  du	  bringst	   stets	   Freude	   in	  mein	  Leben.	  Natascha,	   ich	   bin	   dir	   unaussprechlich	   dankbar	   für	   deine	   grenzenlose	  Herzlichkeit	   sowie	  die	  entspannenden	  Ablenkungen,	  während	  meines	  Studiums	  und	  auch	  während	  der	  Zeit	  meiner	  Promotion.	  	  Martok,	  meine	  tiefe	  Dankbarkeit	  dir	  gegenüber	  kann	  ich	  an	  dieser	  Stelle	  nicht	  annähernd	  beschreiben.	  Dein	  uneingeschränkter	  Rückhalt	  sowie	  deine	  unentwegte	  Motivation	  haben	  meine	  akademische	  Laufbahn	  ermöglicht	  und	  geholfen	  diese	  Dissertation	  zu	  einem	  Erfolg	  zu	  führen.	  Auf	  meinem	  Weg	  bis	  hierher	  hast	  du	  mich	  beständig	  in	  meinen	  Entscheidungen	  unterstützt,	  auch	  wenn	  wir	  dadurch	  zeitweise	  räumlich	  getrennt	  waren.	  Danke	  für	  deine	  Fürsorge,	  Geduld	  und	  Liebe.	  Dir	  widme	  ich	  diese	  Arbeit!	  	   	  
“Leider	  lässt	  sich	  eine	  wahrhafte	  Dankbarkeit	  mit	  Worten	  nicht	  ausdrücken”	  
“Unfortunately	  we	  are	  unable	  to	  express	  in	  words	  genuine	  gratitude”	  	  Johann	  Wolfgang	  von	  Goethe	  	  	  
